Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-0158 in KIT Positive Advanced Solid Tumors
NCT02642016Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Dec 2015
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of barzolvolimab in solid tumor and gastrointestinal stromal tumor (GIST), sponsored by Celldex Therapeutics. Primary endpoint: Dose limiting toxicities for CDX-0158 at 21 days. Started Dec 2015; status: completed.
02
Drugs
barzolvolimab
03
Conditions
solid tumorgastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02642016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642016.